Oncology Research Laboratory

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


397 publications

En préparation
 
Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma
Barras David, Ghisoni Eleonora, Chiffelle Johanna, Orcurto Angela, Dagher Julien, Fahr Noémie, Benedetti Fabrizio, Crespo Isaac, Zimmermann Stefan, Duran Rafael et al., this Pre print is under peer review in Science Immunology.
[DOI][serval:BIB_097A733AD4EC]
 
NFAT5 induction by the tumor microenvironment enforces CD8 T cell exhaustion
Tillé Laure, Cropp Daniela, Bodley Gabrielle, Andreatta Massimo, Charmoy Mélanie, Crespo Isaac, Nassiri Sina, Lourenco Joao, Leblond Marine, Lopez-Rodriguez Cristina et al..
[DOI][serval:BIB_3D15B154D604]
In press
 
Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy - An evaluation of dosimetric performances.
Böhlen T.T., Germond J.F., Desorgher L., Veres I., Bratel A., Landström E., Engwall E., Herrera F.G., Ozsahin E.M., Bourhis J. et al. Radiotherapy and oncology. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_825ACAC4F6E5]
 
Urolithin-A promotes CD8+ T cell-mediated cancer immunosurveillance via FOXO1 activation.
Ginefra P., Hope H.C., Chiang Y.H., Nutten S., Blum S., Coukos G., Vannini N. Cancer research communications. Peer-reviewed.
[DOI][Pmid][serval:BIB_A155196AF6D3]
 
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Lacher S.B., Dörr J., de Almeida G.P., Hönninger J., Bayerl F., Hirschberger A., Pedde A.M., Meiser P., Ramsauer L., Rudolph T.J. et al. Nature. Peer-reviewed.
[DOI][Pmid][serval:BIB_32E213209E57]
 
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al. Nature. Peer-reviewed.
[DOI][Pmid][serval:BIB_5FCB44D6E4AA]
2024
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells.
Croce G., Bobisse S., Moreno D.L., Schmidt J., Guillame P., Harari A., Gfeller D., 2024/04/13. Nature communications, 15 (1) p. 3211. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5F1F27C4B8D4]
Comparison of volumetric modulated arc therapy and helical tomotherapy for prostate cancer using Pareto fronts.
Wüthrich D., Wang Z., Zeverino M., Bourhis J., Bochud F., Moeckli R., 2024/04. Medical physics, 51 (4) pp. 3010-3019. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_49E1CA979679]
 
Proposition de délinéation des volumes cibles anatomocliniques postopératoires de la tumeur primitive des cancers du sinus maxillaire et des cavités nasales [Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers]
Guillemin F., Blanchard P., Boisselier P., Brahimi Y., Calugaru V., Coutte A., Gillon P., Graff P., Liem X., Modesto A. et al., 2024/04. Cancer radiotherapie, 28 (2) pp. 218-227. Peer-reviewed.
[DOI][Pmid][serval:BIB_1A80814091A3]
 
Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia.
Spertini C., Bénéchet A.P., Birch F., Bellotti A., Román-Trufero M., Arber C., Auner H.W., Mitchell R.A., Spertini O., Smirnova T., 2024/03/28. Cell death discovery, 10 (1) p. 157. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7BF16A506AF]
 
A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress-Induced Inflammation.
Martins F., Rosspopoff O., Carlevaro-Fita J., Forey R., Offner S., Planet E., Pulver C., Pak H., Huber F., Michaux J. et al., 2024/03/15. Cancer research, 84 (6) pp. 808-826. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_26A70ECA1060]
Antitumor Effect by Either FLASH or Conventional Dose Rate Irradiation Involves Equivalent Immune Responses.
Almeida A., Godfroid C., Leavitt R.J., Montay-Gruel P., Petit B., Romero J., Ollivier J., Meziani L., Sprengers K., Paisley R. et al., 2024/03/15. International journal of radiation oncology, biology, physics, 118 (4) pp. 1110-1122. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2E833E715DF]
 
Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides.
Ferreira H.J., Stevenson B.J., Pak H., Yu F., Almeida Oliveira J., Huber F., Taillandier-Coindard M., Michaux J., Ricart-Altimiras E., Kraemer A.I. et al., 2024/03/15. Nature communications, 15 (1) p. 2357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6C0EA9079104]
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Guigay J., Ortholan C., Vansteene D., Cupissol D., Even C., Kaminsky M.C., Sire C., Blot E., Debourdeau P., Bozec L. et al., 2024/03. The lancet. Healthy longevity, 5 (3) pp. e182-e193. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_167AAFE038E3]
 
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor A.M., McKeown J., Dimitriou F., Jacques S.K., Zimmer L., Allayous C., Yeoh H.L., Haydon A., Ressler J.M., Galea C. et al., 2024/03. European journal of cancer, 199 p. 113561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB58FC4C5C60]
 
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Rusakiewicz S., Tyekucheva S., Tissot-Renaud S., Chaba K., Imbimbo M., Benedetti F., Kammler R., Hornfeld J., Munzone E., Gianni L. et al., 2024/03. European journal of cancer, 200 p. 113535. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE560AF185F]
 
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques S.K., McKeown J., Grover P., Johnson D.B., Zaremba A., Dimitriou F., Weiser R., Farid M., Namikawa K., Sullivan R.J. et al., 2024/03. European journal of cancer, 199 p. 113563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD78846E78A2]
 
Two to tango: engineered T cells against AML.
Arber C., 2024/02/08. Blood, 143 (6) pp. 476-478. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB6AEE5D9C47]
 
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D., Ghisoni E., Chiffelle J., Orcurto A., Dagher J., Fahr N., Benedetti F., Crespo I., Grimm A.J., Morotti M. et al., 2024/02/02. Science immunology, 9 (92) pp. eadg7995. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A58DD7E390E0]
 
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
Ghasemi A., Martinez-Usatorre A., Li L., Hicham M., Guichard A., Marcone R., Fournier N., Torchia B., Martinez Bedoya D., Davanture S. et al., 2024/02. Nature cancer, 5 (2) pp. 240-261. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DE2DD03AF35]
 
More May Not be Better: Enhanced Spacecraft Shielding May Exacerbate Cognitive Decrements by Increasing Pion Exposures during Deep Space Exploration.
Vozenin M.C., Alaghband Y., Drayson OGG, Piaget F., Leavitt R., Allen B.D., Doan N.L., Rostomyan T., Stabilini A., Reggiani D. et al., 2024/02/01. Radiation research, 201 (2) pp. 93-103. Peer-reviewed.
[DOI][Pmid][serval:BIB_E3D83A58C763]
 
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U., von Braun J., Celis J., Baumann M., Berns A., Eggermont A., Heard E., Heitor M., Chandy M., Chen C.J. et al., 2024/02. Molecular oncology, 18 (2) pp. 245-279. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E812852CFCF3]
 
C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy of Multiple Myeloma Using [99mTc]Tc-PentixaTec.
Enke J.S., Reitsam N.G., Grosser B., Kircher M., Dierks A., Bundschuh R.A., Wienand G., Uhrmacher L., Trepel M., Schottelius M. et al., 2024/01/02. Journal of nuclear medicine, 65 (1) pp. 163-164. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B044D2FE4DC]
A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy.
Rivera J., Digklia A., Christou A.S., Anibal J., Vallis K.A., Wood B.J., Stride E., 2024/01. Ultrasound in medicine & biology, 50 (1) pp. 1-7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E69D2EA7A395]
Dosimetric and biologic intercomparison between electron and proton FLASH beams.
Almeida A., Togno M., Ballesteros-Zebadua P., Franco-Perez J., Geyer R., Schaefer R., Petit B., Grilj V., Meer D., Safai S. et al., 2024/01. Radiotherapy and oncology, 190 p. 109953. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_70503C801F82]
 
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg J.R., Baldomero H., Ansari M., Arber C., Chalandon Y., Daskalakis M., Diepold M., Diesch-Furlanetto T., Duchosal M.A., Gerull S. et al., 2024/01. Hematological oncology, 42 (1) pp. e3241. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BE6179F7211]
 
Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses.
Bourhis J., Sun X.S., Tao Y., 2024. Cellular immunology, 395-396 p. 104772. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_988F5287887C]
 
Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
Limkin E., Blanchard P., Lacas B., Bourhis J., Parmar M., Licitra L., Le Q.T., Yom S.S., Fortpied C., Langendijk J. et al., 2024/01. Radiotherapy and oncology, 190 p. 110011. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3FB310A6F592]
 
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner A., Versluis J.M., Wallace R., Allayous C., Brown L.J., Trojaniello C., Gerard C.L., Jansen Y.J., Bhave P., Neyns B. et al., 2024/01. European journal of cancer, 196 p. 113441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2852520524D8]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study.
Rossi E., Boldrini L., Maratta M.G., Gatta R., Votta C., Tortora G., Schinzari G., 2023/12/31. Human vaccines & immunotherapeutics, 19 (1) p. 2172926. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BFEA01D27F95]
 
HIV vaccines induce CD8<sup>+</sup> T cells with low antigen receptor sensitivity.
Migueles S.A., Nettere D.M., Gavil N.V., Wang L.T., Toulmin S.A., Kelly E.P., Ward A.J., Lin S., Thompson S.A., Peterson B.A. et al., 2023/12/15. Science, 382 (6676) pp. 1270-1276. Peer-reviewed.
[DOI][Pmid][serval:BIB_16798A6A6CBC]
 
A Novel Platform for Evaluating Dose Rate Effects on Oxidative Damage to Peptides: Toward a High-Throughput Method to Characterize the Mechanisms Underlying the FLASH Effect.
Gupta S., Inman J.L., Chant J., Obst-Huebl L., Nakamura K., Costello S.M., Marqusee S., Mao J.H., Kunz L., Paisley R. et al., 2023/12/01. Radiation research, 200 (6) pp. 523-530. Peer-reviewed.
[DOI][Pmid][serval:BIB_5F9CBBBC22DA]
 
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ.
Newey A., Yu L., Barber L.J., Choudhary J.S., Bassani-Sternberg M., Gerlinger M., 2023/11/17. Cancer research communications, 3 (11) pp. 2345-2357. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_247CD6A9F993]
 
Effect of Conventional and Ultrahigh Dose Rate FLASH Irradiations on Preclinical Tumor Models: A Systematic Analysis.
Böhlen T.T., Germond J.F., Petersson K., Ozsahin E.M., Herrera F.G., Bailat C., Bochud F., Bourhis J., Moeckli R., Adrian G., 2023/11/15. International journal of radiation oncology, biology, physics, 117 (4) pp. 1007-1017. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E35A0EBD9890]
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M., Huber F., Arnaud M., Kraemer A.I., Altimiras E.R., Michaux J., Taillandier-Coindard M., Chiffelle J., Murgues B., Gehret T. et al., 2023/11/14. Immunity, 56 (11) pp. 2650-2663.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_809F4EAB21AB]
 
Need for standardization in the use of structures in the intensity-modulated radiation therapy planning of head and neck cancers, a GORTEC study.
Özer Ö., Shafi H., O'Reilly D., Loiseau C., Dejean C., Bourhis J., Thariat J., 2023/11. Radiotherapy and oncology, 188 p. 109895. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1B42004D5655]
 
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D., Woodford R., Menzies A.M., Zimmer L., Williamson A., Ramelyte E., Dimitriou F., Wicky A., Wallace R., Mallardo M. et al., 2023/10/25. Journal of translational medicine, 21 (1) p. 753. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_79C70FD3661F]
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Cuendet M., Muet F., Aedo-Lopez V. et al., 2023/10/18. JMIR research protocols, 12 pp. e48386. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB6569F97D27]
 
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D. et al., 2023/10. Nature cancer, 4 (10) pp. 1410-1417. Peer-reviewed.
[DOI][Pmid][serval:BIB_E6692BB52E6C]
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
Tillé L., Cropp D., Charmoy M., Reichenbach P., Andreatta M., Wyss T., Bodley G., Crespo I., Nassiri S., Lourenco J. et al., 2023/10. Nature immunology, 24 (10) pp. 1645-1653. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B944FAF7B77]
Clinical implementation of deep learning-based automated left breast simultaneous integrated boost radiotherapy treatment planning.
Zeverino M., Piccolo C., Wuethrich D., Jeanneret-Sozzi W., Marguet M., Bourhis J., Bochud F., Moeckli R., 2023/10. Physics and imaging in radiation oncology, 28 p. 100492. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_03629A515559]
 
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery.
Zhang B., Bassani-Sternberg M., 2023/10. Journal for immunotherapy of cancer, 11 (10) pp. e007073. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_41E48A349A10]
 
Dosimetry of the PIM1 Pion Beam at the Paul Scherrer Institute for Radiobiological Studies of Mice.
Desorgher L., Stabilini A., Rostomyan T., Reggiani D., Hajdas W., Marcinkowski R.M., Vozenin M.C., Limoli C.L., Yukihara E.G., Bailat C., 2023/10/01. Radiation research, 200 (4) pp. 357-365. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BAE3CAA4E2E0]
Influence of optimisation parameters on directly deliverable Pareto fronts explored for prostate cancer.
Wüthrich D., Zeverino M., Bourhis J., Bochud F., Moeckli R., 2023/10. Physica medica, 114 p. 103139. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FC036C4B1A6]
 
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
Caserta C., Nucera S., Barcella M., Fazio G., Naldini M.M., Pagani R., Pavesi F., Desantis G., Zonari E., D'Angiò M. et al., 2023/10. Leukemia, 37 (10) pp. 1994-2005. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_27B8A2CE71A6]
 
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K., Zygoura P., Norkin M., Tissot S., Shakarishvili N., Popat S., Curioni-Fontecedro A., O'Brien M., Pope A., Shah R. et al., 2023/10. Journal for immunotherapy of cancer, 11 (10). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03AE420D2700]
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
Apostolova P., Kreutmair S., Toffalori C., Punta M., Unger S., Burk A.C., Wehr C., Maas-Bauer K., Melchinger W., Haring E. et al., 2023/10. British journal of haematology, 203 (2) pp. 264-281. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_34E444E517E5]
 
Deep learning predictions of TCR-epitope interactions reveal epitope-specific chains in dual alpha T cells
Giancarlo Croce, Sara Bobisse, Dana Léa Moreno, Julien Schmidt, Philippe Guillame, Alexandre Harari, David Gfeller, 2023/09/16..
[DOI][serval:BIB_0A68625521D8]
3D-conformal very-high energy electron therapy as candidate modality for FLASH-RT: A treatment planning study for glioblastoma and lung cancer.
Böhlen T.T., Germond J.F., Traneus E., Vallet V., Desorgher L., Ozsahin E.M., Bochud F., Bourhis J., Moeckli R., 2023/09. Medical physics, 50 (9) pp. 5745-5756. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE91AE049264]
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
Reichenbach P., Giordano Attianese GMP, Ouchen K., Cribioli E., Triboulet M., Ash S., Saillard M., Vuillefroy de Silly R., Coukos G., Irving M., 2023/09. Nature biomedical engineering, 7 (9) pp. 1063-1080. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_22CADB5FE4EC]
 
Reductive carboxylation epigenetically instructs T cell differentiation.
Jaccard A., Wyss T., Maldonado-Pérez N., Rath J.A., Bevilacqua A., Peng J.J., Lepez A., Von Gunten C., Franco F., Kao K.C. et al., 2023/09. Nature, 621 (7980) pp. 849-856. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D1AE6E79E2FB]
The sparing effect of FLASH-RT on synaptic plasticity is maintained in mice with standard fractionation.
Limoli C.L., Kramár E.A., Almeida A., Petit B., Grilj V., Baulch J.E., Ballesteros-Zebadua P., Loo B.W., Wood M.A., Vozenin M.C., 2023/09. Radiotherapy and oncology, 186 p. 109767. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4275AE8CF8AF]
What Can Ribo-Seq, Immunopeptidomics, and Proteomics Tell Us About the Noncanonical Proteome?
Prensner J.R., Abelin J.G., Kok L.W., Clauser K.R., Mudge J.M., Ruiz-Orera J., Bassani-Sternberg M., Moritz R.L., Deutsch E.W., van Heesch S., 2023/09. Molecular & cellular proteomics, 22 (9) p. 100631. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FC2F4DA59A98]
 
Développements récents en hématologie, Partie 2
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/23. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_E9D38C229944]
 
Développements récents en hématologie, Teil 1
Duchosal Michel A., Alberio Lorenzo, Angelillo-Scherrer Anne, Arber Caroline, Balabanov Stefan, Blum Sabine, Bttcher Steffen, Buser Andreas, Cairoli Anne, Chalandon Yves et al., 2023/08/16. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_BEEE6D0FAED7]
 
EPAC1 inhibition protects the heart from doxorubicin-induced toxicity.
Mazevet M., Belhadef A., Ribeiro M., Dayde D., Llach A., Laudette M., Belleville T., Mateo P., Gressette M., Lefebvre F. et al., 2023/08/08. eLife, 12 pp. e83831. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_55FAD703BC5E]
 
Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy.
Le Reun E., Granzotto A., Pêtre A., Bodgi L., Beldjoudi G., Lacornerie T., Vallet V., Bouchet A., Al-Choboq J., Bourguignon M. et al., 2023/08/05. Cancers, 15 (15) p. 3979. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BEF17EF87EE2]
 
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers.
Bill R., Wirapati P., Messemaker M., Roh W., Zitti B., Duval F., Kiss M., Park J.C., Saal T.M., Hoelzl J. et al., 2023/08/04. Science, 381 (6657) pp. 515-524. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17A3A9510B2F]
 
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study.
Rossi A., Aimar G., Audisio M., Bungaro M., Caglio A., Di Liello R., Gamba T., Gargiulo P., Ghisoni E., Lombardi P. et al., 2023/08. European journal of cancer, 189 p. 112920. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C4030FF425F]
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
Tao Y., Sun X.S., Pointreau Y., Tourneau C.L., Sire C., Gollmer K., Crompton P., Bourhis J., 2023/08. Future oncology, 19 (26) pp. 1769-1776. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_41AB188BFB77]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
 
Nondestructive 3D pathology with analysis of nuclear features for prostate cancer risk assessment.
Serafin R., Koyuncu C., Xie W., Huang H., Glaser A.K., Reder N.P., Janowczyk A., True L.D., Madabhushi A., Liu J.T., 2023/08. The Journal of pathology, 260 (4) pp. 390-401. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_654B15089D4E]
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Aedo-Lopez V., Mederos N., Latifyan S. et al., 2023/07/22. Supportive care in cancer, 31 (8) p. 484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC47A57CA4E0]
 
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Tuninetti V., Pace L., Ghisoni E., Quarà V., Arezzo F., Palicelli A., Mandato V.D., Geuna E., Cormio G., Biglia N. et al., 2023/07/15. Cancers, 15 (14) p. 3639. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2631A37FECDF]
 
Restoring tumor immunogenicity with dendritic cell reprogramming.
Zimmermannova O., Ferreira A.G., Ascic E., Velasco Santiago M., Kurochkin I., Hansen M., Met Ö., Caiado I., Shapiro I.E., Michaux J. et al., 2023/07/14. Science immunology, 8 (85) pp. eadd4817. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_73DE683143CE]
High-throughput spatiotemporal monitoring of single-cell secretions via plasmonic microwell arrays.
Ansaryan S., Liu Y.C., Li X., Economou A.M., Eberhardt C.S., Jandus C., Altug H., 2023/07. Nature biomedical engineering, 7 (7) pp. 943-958. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D315037EB809]
A microfluidics-enabled automated workflow of sample preparation for MS-based immunopeptidomics.
Li X., Pak H.S., Huber F., Michaux J., Taillandier-Coindard M., Altimiras E.R., Bassani-Sternberg M., 2023/06/26. Cell reports methods, 3 (6) p. 100479. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_124E229FADE6]
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J., Guillaume P., Schmidt J., Michaux J., Larabi A., Lau K., Perez MAS, Croce G., Genolet R., Coukos G. et al., 2023/06/13. Immunity, 56 (6) pp. 1359-1375.e13. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9BA5A00EAA19]
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R., Lozano L.E., Anastasio A., Lofek S., Mastelic-Gavillet B., Navarro Rodrigo B., Nguyen S., Dartiguenave F., Rodrigues-Dias S.C., Cesson V. et al., 2023/06/08. Cancers, 15 (12) p. 3114. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4F3B91EA43E2]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
 
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94155F804FBD]
 
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C., Dummer R., Amaral T., Amaria R.N., Ascierto P.A., Burton E.M., Dreno B., Eggermont AMM, Hauschild A., Hoeller C. et al., 2023/06. Nature medicine, 29 (6) pp. 1310-1312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_079BED918172]
 
Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulation.
Meziani L., Gerbé de Thoré M., Clémenson C., Liu W., Laurent P.A., Mondini M., Vozenin M.C., Deutsch E., 2023/06. Journal for immunotherapy of cancer, 11 (6) pp. e006846. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4E1994F97409]
 
Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.
Petit C., Lee A., Ma J., Lacas B., Ng W.T., Chan ATC, Hong R.L., Chen M.Y., Chen L., Li W.F. et al., 2023/06. The Lancet. Oncology, 24 (6) pp. 611-623. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F33F59DE3516]
Computational design of dynamic receptor-peptide signaling complexes applied to chemotaxis.
Jefferson R.E., Oggier A., Füglistaler A., Camviel N., Hijazi M., Villarreal A.R., Arber C., Barth P., 2023/05/19. Nature communications, 14 (1) p. 2875. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F1996DB956D]
 
Generation of a novel synthetic CD8<sup>+</sup> T cell state that leads to tumor control in mice.
Corria-Osorio J., Coukos G., 2023/05. Nature immunology, 24 (5) pp. 755-756. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B121C8D85A4]
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio J., Carmona S.J., Stefanidis E., Andreatta M., Ortiz-Miranda Y., Muller T., Rota I.A., Crespo I., Seijo B., Castro W. et al., 2023/05. Nature immunology, 24 (5) pp. 869-883. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6529135A8DD]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
Successful outcome of pregnancy post-allogeneic stem cell transplant despite severe RH1 alloimmunization: A case report.
Gavillet M., Rufer N., Grandoni F., Rizzi M., Vulliemoz N., Baud D., Alberio L., Canellini G., Legardeur H., 2023/05. British journal of haematology, 201 (3) pp. 581-584. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3EEAE834742]
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Kraemer A.I., Chong C., Huber F., Pak H., Stevenson B.J., Müller M., Michaux J., Altimiras E.R., Rusakiewicz S., Simó-Riudalbas L. et al., 2023/05. Nature cancer, 4 (5) pp. 608-628. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AFB188A208B6]
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R., Bobisse S., Chiffelle J., Arnaud M., Petremand R., Queiroz L., Michel A., Reichenbach P., Cesbron J., Auger A. et al., 2023/04/24. Cell reports methods, 3 (4) p. 100459. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AC23FF064822]
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Fritah H., Graciotti M., Lai-Lai Chiang C., Huguenin-Bergenat A.L., Petremand R., Ahmed R., Guillaume P., Schmidt J., Stevenson B.J., Gfeller D. et al., 2023/04/21. iScience, 26 (4) p. 106288. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5198D931AE8]
Independent Reproduction of the FLASH Effect on the Gastrointestinal Tract: A Multi-Institutional Comparative Study.
Valdés Zayas A., Kumari N., Liu K., Neill D., Delahoussaye A., Gonçalves Jorge P., Geyer R., Lin S.H., Bailat C., Bochud F. et al., 2023/04/02. Cancers, 15 (7) p. 2121. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65710DEED677]
Toxicity, quality of life, and PSA control after 50 Gy stereotactic body radiation therapy to the dominant intraprostatic nodule with the use of a rectal spacer: results of a phase I/II study.
Cloitre M., Valerio M., Mampuya A., Rakauskas A., Berthold D., Tawadros T., Meuwly J.Y., Heym L., Duclos F., Vallet V. et al., 2023/04/01. The British journal of radiology, 96 (1145) p. 20220803. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB3AC2C2AFDE]
 
A neutrophil response linked to tumor control in immunotherapy.
Gungabeesoon J., Gort-Freitas N.A., Kiss M., Bolli E., Messemaker M., Siwicki M., Hicham M., Bill R., Koch P., Cianciaruso C. et al., 2023/03/30. Cell, 186 (7) pp. 1448-1464.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_75BDBCD58180]
 
In Reply to Horst et al.
Böhlen T.T., Germond J.F., Bochud F., Bailat C., Moeckli R., Bourhis J., Vozenin M.C., Ozsahin E.M., 2023/03/15. International journal of radiation oncology, biology, physics, 115 (4) pp. 1007-1009. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1EAB447A4311]
CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions.
Liu P.S., Chen Y.T., Li X., Hsueh P.C., Tzeng S.F., Chen H., Shi P.Z., Xie X., Parik S., Planque M. et al., 2023/03. Nature immunology, 24 (3) pp. 452-462. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E5287AECF4CC]
Salvage LATTICE radiotherapy for a growing tumour despite conventional radio chemotherapy treatment of lung cancer.
Kinj R., Casutt A., Nguyen-Ngoc T., Mampuya A., Schiappacasse L., Bourhis J., Huck C., Patin D., Marguet M., Zeverino M. et al., 2023/03. Clinical and translational radiation oncology, 39 p. 100557. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FD65C693CBE6]
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E552B0535E6B]
The impact of immunopeptidomics: From basic research to clinical implementation.
Shapiro I.E., Bassani-Sternberg M., 2023/03. Seminars in immunology, 66 p. 101727. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6B56B0492D5F]
Dendritic cells direct circadian anti-tumour immune responses.
Wang C., Barnoud C., Cenerenti M., Sun M., Caffa I., Kizil B., Bill R., Liu Y., Pick R., Garnier L. et al., 2023/02. Nature, 614 (7946) pp. 136-143. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33489F389D05]
Multi-site cross-organ calibrated deep learning (MuSClD): Automated diagnosis of non-melanoma skin cancer.
Zhou Y., Koyuncu C., Lu C., Grobholz R., Katz I., Madabhushi A., Janowczyk A., 2023/02. Medical image analysis, 84 p. 102702. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_576D871C7998]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
 
A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD+ metabolism.
Maric T., Bazhin A., Khodakivskyi P., Mikhaylov G., Solodnikova E., Yevtodiyenko A., Giordano Attianese GMP, Coukos G., Irving M., Joffraud M. et al., 2023/01/15. Biosensors & bioelectronics, 220 p. 114826. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C15EADDDA9C7]
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8<sup>+</sup> T cells and reprogramming macrophages.
Tichet M., Wullschleger S., Chryplewicz A., Fournier N., Marcone R., Kauzlaric A., Homicsko K., Deak L.C., Umaña P., Klein C. et al., 2023/01/10. Immunity, 56 (1) pp. 162-179.e6. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D37AF3A7C808]
Case report: First-in-human combined low-dose whole-heart irradiation and high-dose stereotactic arrhythmia radioablation for immunosuppressive refractory cardiac sarcoidosis and ventricular tachycardia.
van der Ree M.H., Herrera Siklody C., Le Bloa M., Pascale P., Porretta A.P., Teres C.C., Solana Munoz J., Luca A., Domenichini G., Ozasahin M. et al., 2023. Frontiers in cardiovascular medicine, 10 p. 1213165. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FA14CF085E93]
 
Overall avidity declines in TCR repertoires during latent CMV but not EBV infection.
Couturaud B., Doix B., Carretero-Iglesia L., Allard M., Pradervand S., Hebeisen M., Rufer N., 2023. Frontiers in immunology, 14 p. 1293090. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC9F31B195B6]
 
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y., Biau J., Sun X.S., Sire C., Martin L., Alfonsi M., Prevost J.B., Modesto A., Lafond C., Tourani J.M. et al., 2023/01. Annals of oncology, 34 (1) pp. 101-110. Peer-reviewed.
[DOI][Pmid][serval:BIB_5988D0B3696F]
Postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancers with high-risk margins: A dosimetric comparison of volumetric modulated arc therapy with or without non-coplanar arcs and acute toxicity outcomes from the STEREOPOSTOP GORTEC 2017-03 phase 2 trial.
Biau J., Lopez L., Thivat E., Casile M., Millardet C., Saroul N., Pham-Dang N., Molnar I., Bourhis J., Lapeyre M., 2023/01. Clinical and translational radiation oncology, 38 pp. 169-174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DB540CCA7ED5]
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
Arnaud M., Coukos G., Harari A., 2023/01. Clinical and translational medicine, 13 (1) pp. e1174. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_803001E6E3E3]
 
Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy.
Gachoud D., Bertelli C., Rufer N., 2023/01. British journal of haematology, 200 (2) pp. e25-e27. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4E3F68CC193D]
2022
 
Genetics and anatomy sculpt immune-cell partners of ovarian cancer
Dangaj Laniti Denarda, Coukos George, 2022/12/22. Nature, 612 (7941) pp. 634-636. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01D5FAC4C129]
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Gautron Moura B., Gerard C.L., Testart N., Caikovski M., Wicky A., Aedo-Lopez V., Berthod G., Homicsko K., Prior J.O., Dromain C. et al., 2022/12/21. Cancers, 15 (1) p. 31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AF72365A8C3]
 
TIL Therapy Entering the Mainstream.
Coukos G., 2022/12/08. The New England journal of medicine, 387 (23) pp. 2185-2186. Peer-reviewed.
[DOI][Pmid][serval:BIB_0B993D925FDD]
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
 
AIRO GORTEC consensus on postoperative radiotherapy (PORT) in low-intermediate risk early stages oral squamous cell cancers (OSCC).
Merlotti A., Alterio D., Orlandi E., Racadot S., Bonomo P., Franco P., D'Angelo E., Ursino S., Pointreau Y., Lapeyre M. et al., 2022/12. Radiotherapy and oncology, 177 pp. 95-104. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A8EE44EDCADD]
 
FLASHlab@PITZ: New R&D platform with unique capabilities for electron FLASH and VHEE radiation therapy and radiation biology under preparation at PITZ.
Stephan F., Gross M., Grebinyk A., Aboulbanine Z., Amirkhanyan Z., Budach V., Ehrhardt V.H., Faus-Golfe A., Frohme M., Germond J.F. et al., 2022/12. Physica medica, 104 pp. 174-187. Peer-reviewed.
[DOI][Pmid][serval:BIB_B4F1E1A64EA0]
 
IL-2 engineered MSCs rescue T cells in tumours.
Irving M., Ortiz-Miranda Y., Coukos G., 2022/12. Nature cell biology, 24 (12) pp. 1689-1691. Peer-reviewed.
[DOI][Pmid][serval:BIB_A1B1B8C4A855]
 
Normal Tissue Sparing by FLASH as a Function of Single-Fraction Dose: A Quantitative Analysis.
Böhlen T.T., Germond J.F., Bourhis J., Vozenin M.C., Ozsahin E.M., Bochud F., Bailat C., Moeckli R., 2022/12/01. International journal of radiation oncology, biology, physics, 114 (5) pp. 1032-1044. Peer-reviewed.
[DOI][Pmid][serval:BIB_03FA7A108554]
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.
Ghisoni E., Morotti M., Colomer-Lahiguera S., Eicher M., Coukos G., Trueb L., Di Maio M., 2022/12. Journal for immunotherapy of cancer, 10 (12) pp. e006082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E61BEAAE8B5E]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen T.T., Germond J.F., Bourhis J., Bailat C., Bochud F., Moeckli R., 2022/12. Medical physics, 49 (12) pp. 7672-7682. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5B6F25E2105]
 
Towards clinical translation of FLASH radiotherapy.
Vozenin M.C., Bourhis J., Durante M., 2022/12. Nature reviews. Clinical oncology, 19 (12) pp. 791-803. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7711B81AAACB]
3D-Beacons: decreasing the gap between protein sequences and structures through a federated network of protein structure data resources.
Varadi M., Nair S., Sillitoe I., Tauriello G., Anyango S., Bienert S., Borges C., Deshpande M., Green T., Hassabis D. et al., 2022/11/30. GigaScience, 11 pp. giac118. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8AF1FE2C8116]
 
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.
Zeng Q., Saghafinia S., Chryplewicz A., Fournier N., Christe L., Xie Y.Q., Guillot J., Yucel S., Li P., Galván J.A. et al., 2022/11/18. Science, 378 (6621) pp. eabl7207. Peer-reviewed.
[DOI][Pmid][serval:BIB_324086550512]
 
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents.
Gachoud D., Pillonel T., Tsilimidos G., Battolla D., Dumas D., Opota O., Fontana S., Vollenweider P., Manuel O., Greub G. et al., 2022/11. British journal of haematology, 199 (4) pp. 549-559. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_801AF06A907A]
Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
Camviel Nicolas, Wolf Benita, Croce Giancarlo, Gfeller David, Zoete Vincent, Arber Caroline, 2022/11. Journal for ImmunoTherapy of Cancer, 10 (11) pp. e005091. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F15484E457D0]
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A., Dettorre G.M., Dafni U., Aguilar-Company J., Castelo-Branco L., Lambertini M., Gennatas S., Angelis V., Sita-Lumsden A., Rogado J. et al., 2022/11. Journal for immunotherapy of cancer, 10 (11) pp. e005732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43EB088625EB]
 
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.
Kandalaft L.E., Dangaj Laniti D., Coukos G., 2022/11. Nature reviews. Cancer, 22 (11) pp. 640-656. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B0D5013539C]
Refractory ventricular tachycardia treated by a second session of stereotactic arrhythmia radioablation.
Herrera Siklody C., Pruvot E., Pascale P., Kinj R., Jumeau R., Le Bloa M., Teres C., Domenichini G., Porretta A.P., Ozsahin M. et al., 2022/11. Clinical and translational radiation oncology, 37 pp. 89-93. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0DB36A9EB031]
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat Hematologic Malignancies
Stadelmann Raphael, Cairoli Anne, Arber Caroline, 2022/10/31. healthbook TIMES Oncology Hematology - Edition 3 / 2022 13. Peer-reviewed.
[URN][DOI][serval:BIB_99272140464E]
 
Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity.
Chryplewicz A., Scotton J., Tichet M., Zomer A., Shchors K., Joyce J.A., Homicsko K., Hanahan D., 2022/10/10. Cancer cell, 40 (10) pp. 1111-1127.e9. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D8C0A81E8E9D]
 
FLASH Radiotherapy & Particle Therapy conference, FRPT2021.
Vozenin M.C., Schüller A., Dutreix M., Kirkby K., Baumann M., Coppes R.P., Thwaites D., 2022/10. Radiotherapy and oncology, 175 pp. 167-168. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_835E1B1C60D6]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Towards a national strategy for digital pathology in Switzerland.
Janowczyk A., Baumhoer D., Dirnhofer S., Grobholz R., Kipar A., de Leval L., Merkler D., Michielin O., Moch H., Perren A. et al., 2022/10. Virchows Archiv, 481 (4) pp. 647-652. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_329EB5DFD086]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
Comparison of ultra-high versus conventional dose rate radiotherapy in a patient with cutaneous lymphoma.
Gaide O., Herrera F.G., Jeanneret Sozzi W., Gonçalves Jorge P., Kinj R., Bailat C., Duclos F., Bochud F., Germond J.F., Gondré M. et al., 2022/09. Radiotherapy and oncology, 174 pp. 87-91. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3BC621CB1990]
Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs.
Rohrer Bley C., Wolf F., Gonçalves Jorge P., Grilj V., Petridis I., Petit B., Böhlen T.T., Moeckli R., Limoli C., Bourhis J. et al., 2022/09/01. Clinical cancer research, 28 (17) pp. 3814-3823. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_83A4D24300BD]
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O., Zhou C., Rogado J., Huddar P., Shotton R., Tivey A., Albiges L., Angelakas A., Arnold D., Aung T. et al., 2022/08/16. Cancers, 14 (16) p. 3931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB438C1281CE]
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P., Schmidt J., Costa-Nunes C.M., Bordry N., Guillaume P., Luescher I., Speiser D.E., Rufer N., Hebeisen M., 2022/08/10. Frontiers in immunology, 13 p. 973986. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_16DFBAE86CE1]
 
Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar A., Champagne J., Nagel R., Kenski J., Laos M., Michaux J., Pak H.S., Bleijerveld O.B., Mordente K., Navarro J.M. et al., 2022/08..
[DOI][WoS][Pmid][serval:BIB_9B120DBE92DE]
Commissioning and validation of RayStation treatment planning system for CyberKnife M6.
Gondré M., Conrad M., Vallet V., Bourhis J., Bochud F., Moeckli R., 2022/08. Journal of applied clinical medical physics, 23 (8) pp. e13732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86D6807F70CB]
 
Microfluidic T Cell Selection by Cellular Avidity.
Ashby J.F., Schmidt J., Kc N., Kurum A., Koch C., Harari A., Tang L., Au S.H., 2022/08. Advanced healthcare materials, 11 (16) pp. e2200169. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9101DBCC66E2]
 
Structure-based prediction of BRAF mutation classes using machine-learning approaches.
Krebs F.S., Britschgi C., Pradervand S., Achermann R., Tsantoulis P., Haefliger S., Wicki A., Michielin O., Zoete V., 2022/07/22. Scientific reports, 12 (1) p. 12528. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CB3AA02B4B8]
 
Immune pressure sculps tumor cells and trims high-quality mutations.
Bassani-Sternberg M., Harari A., 2022/07/11. Cancer cell, 40 (7) pp. 717-719. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4774C8AD358C]
A new mouse model of radiation-induced liver disease reveals mitochondrial dysfunction as an underlying fibrotic stimulus.
Melin N., Yarahmadov T., Sanchez-Taltavull D., Birrer F.E., Brodie T.M., Petit B., Felser A., Nuoffer J.M., Montani M., Vozenin M.C. et al., 2022/07. JHEP reports, 4 (7) p. 100508. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0CD190CF6BA1]
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Ochoa-de-Olza M., Bourhis J., Coukos G., Herrera F.G., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004939. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DBBB9D3370A5]
 
Author Correction: Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06..
[DOI][WoS][Pmid][serval:BIB_60BF1DA61627]
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S. et al., 2022/06. ESMO open, 7 (3) p. 100499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_880DB2367FE3]
 
International assessment of interobserver reproducibility of flap delineation in head and neck carcinoma.
Beddok A., Guzene L., Coutte A., Thomson D., Yom S.S., Calugaru V., Blais E., Gilliot O., Racadot S., Pointreau Y. et al., 2022/06. Acta oncologica, 61 (6) pp. 672-679. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ECADD78C324F]
Deciphering the landscape of phosphorylated HLA-II ligands.
Solleder M., Racle J., Guillaume P., Coukos G., Bassani-Sternberg M., Gfeller D., 2022/05/20. iScience, 25 (5) p. 104215. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_54BD67DD87D2]
Prise en charge des métastases cérébrales en 2022 [Management of brain metastases in 2022]
Schiappacasse L., Kinj R., De Micheli R., Mederos N., Tuleasca C., Cossu G., Dunet V., Levivier M., Bourhis J., Hottinger A.F., 2022/05/18. Revue medicale suisse, 18 (782) pp. 976-983. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C341F49A8ECA]
 
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Digklia A., Coukos G., Homicsko K., 2022/05/02. Clinical cancer research, 28 (9) pp. 1745-1747. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0CAC463D4200]
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee R.J., Wysocki O., Zhou C., Shotton R., Tivey A., Lever L., Woodcock J., Albiges L., Angelakas A., Arnold D. et al., 2022/05. JCO clinical cancer informatics, 6 pp. e2100177. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5BE25E8275C]
Machine Learning to Predict Risk of Relapse Using Cytologic Image Markers in Patients With Acute Myeloid Leukemia Posthematopoietic Cell Transplantation.
Arabyarmohammadi S., Leo P., Viswanathan V.S., Janowczyk A., Corredor G., Fu P., Meyerson H., Metheny L., Madabhushi A., 2022/05. JCO clinical cancer informatics, 6 pp. e2100156. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C24FD79A1874]
 
Radiographic-anatomy, natural history and extension pathways of parotid and submandibular gland cancers.
Biau J., Nutting C., Langendijk J.A., Frédéric-Moreau T., Thariat J., Piram L., Bellini R., Saroul N., Pham Dang N., O'Sullivan B. et al., 2022/05. Radiotherapy and oncology, 170 pp. 48-54. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FE2485183E1]
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
Arnaud M., Chiffelle J., Genolet R., Navarro Rodrigo B., Perez MAS, Huber F., Magnin M., Nguyen-Ngoc T., Guillaume P., Baumgaertner P. et al., 2022/05. Nature biotechnology, 40 (5) pp. 656-660. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18BFBDDF727B]
 
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J., Burtness B., Licitra L.F., Nutting C., Schoenfeld J.D., Omar M., Bouisset F., Nauwelaerts H., Urfer Y., Zanna C. et al., 2022/05. Future oncology, 18 (14) pp. 1669-1678. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A17DBE552A8]
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
Omer B., Cardenas M.G., Pfeiffer T., Daum R., Huynh M., Sharma S., Nouraee N., Xie C., Tat C., Perconti S. et al., 2022/04/01. Cancer immunology research, 10 (4) pp. 512-524. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78535A53B294]
 
A new workflow combining magnetic cell separation and impedance-based cell dispensing for gentle, simple and reliable cloning of specific CD8+ T cells.
Ben Khelil M., Aeberli L., Perchaud M., Genolet R., Abdeljaoued S., Borg C., Binda D., Harari A., Jandus C., Muller G. et al., 2022/04. SLAS technology, 27 (2) pp. 130-134. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97892CDB341E]
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
Ochoa-de-Olza M., Bourhis J., Coukos G., Herrera F.G., 2022/04. The Lancet. Oncology, 23 (4) pp. e157. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC56553604E1]
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.
Nardou K., Nicolas M., Kuttler F., Cisarova K., Celik E., Quinodoz M., Riggi N., Michielin O., Rivolta C., Turcatti G. et al., 2022/03/19. Cancers, 14 (6) p. 1575. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_878327B7BEC9]
 
Lighting up the tumor fire with low-dose irradiation.
Herrera F.G., Romero P., Coukos G., 2022/03. Trends in immunology, 43 (3) pp. 173-179. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_49751A0F49EB]
 
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates.
Lichti C.F., Vigneron N., Clauser K.R., Van den Eynde B.J., Bassani-Sternberg M., 2022/03/01. Cancer immunology research, 10 (3) pp. 275-284. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_81D3B5D58DAB]
Technical note: Validation of an ultrahigh dose rate pulsed electron beam monitoring system using a current transformer for FLASH preclinical studies.
Gonçalves Jorge P., Grilj V., Bourhis J., Vozenin M.C., Germond J.F., Bochud F., Bailat C., Moeckli R., 2022/03. Medical physics, 49 (3) pp. 1831-1838. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D66CA0261E74]
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.
Pataskar A., Champagne J., Nagel R., Kenski J., Laos M., Michaux J., Pak H.S., Bleijerveld O.B., Mordente K., Navarro J.M. et al., 2022/03. Nature, 603 (7902) pp. 721-727. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ED604B40AD79]
Nurse-Led Consultation and Symptom Burden in Patients with Head and Neck Cancer: A Comparative Analysis of Routine Clinical Data.
Luta X., Colomer-Lahiguera S., Martins Cardoso R.J., Hof F., Savoie M., Schuler C., Wicht J., Fucina N., Debarge P., Ninane F. et al., 2022/02/26. Cancers, 14 (5) p. 1227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CAA0E94D9DB3]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
 
Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives.
Kinj R., Muggeo E., Schiappacasse L., Bourhis J., Herrera F.G., 2022/02/23. Cancers, 14 (5) p. 1152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1222E7500D6E]
PARP inhibition in ovarian cancer: what is still missing?
Morotti M., Ghisoni E., 2022/02/15. European Journal of Gynaecological Oncology, 43 (1) pp. 143-145.
[URN][WoS][serval:BIB_66073FABE67C]
High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure.
Schrijver I.T., Karakike E., Théroude C., Baumgartner P., Harari A., Giamarellos-Bourboulis E.J., Calandra T., Roger T., 2022/02/11. Intensive care medicine experimental, 10 (1) p. 5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79AC142AD176]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
Can UHDR devices with only a few fixed beams provide competitive treatments plans compared to VMAT?
Böhlen T. T., Germond J.-F., Traneus E., Desorgher L., Vozenin M.-C., Bourhis J., Bailat C., Bochud F., Moeckli R., 2022/02. Physica Medica, 94 pp. S37–S38.
[DOI][serval:BIB_2C7196825B4E]
 
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger S.M., Buder-Bakhaya K., Lo S.N., Forschner A., McKean M., Zimmer L., Khoo C., Dummer R., Eroglu Z., Buchbinder E.I. et al., 2022/02. European journal of cancer, 162 pp. 22-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC41A790D28F]
 
Identification of tumor antigens with immunopeptidomics.
Chong C., Coukos G., Bassani-Sternberg M., 2022/02. Nature biotechnology, 40 (2) pp. 175-188. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0938B9EC9DC3]
 
Polymer Nanoparticle-Mediated Delivery of Oxidized Tumor Lysate-Based Cancer Vaccines.
Berti C., Graciotti M., Boarino A., Yakkala C., Kandalaft L.E., Klok H.A., 2022/02. Macromolecular bioscience, 22 (2) pp. e2100356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_561527E3BDD3]
Validation of Monte Carlo dose calculation algorithm for CyberKnife multileaf collimator.
Gondré M., Marsolat F., Bourhis J., Bochud F., Moeckli R., 2022/02. Journal of applied clinical medical physics, 23 (2) pp. e13481. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5E1F27A9CF4B]
 
High-Throughput Single-Cell TCR-pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit.
Jammes F., Schmidt J., Coukos G., Maerkl S.J., 2022/01/28. ACS sensors, 7 (1) pp. 159-165. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3E11871D7007]
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fierle J.K., Abram-Saliba J., Atsaves V., Brioschi M., de Tiani M., Reichenbach P., Irving M., Coukos G., Dunn S.M., 2022/01/21. Scientific reports, 12 (1) p. 1136. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D41964E1822]
Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis.
Xie W., Reder N.P., Koyuncu C., Leo P., Hawley S., Huang H., Mao C., Postupna N., Kang S., Serafin R. et al., 2022/01/15. Cancer research, 82 (2) pp. 334-345. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4CB64CF66EFE]
The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience.
Bragina M.E., Daina A., Perez MAS, Michielin O., Zoete V., 2022/01/12. International journal of molecular sciences, 23 (2) p. 811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9174E37AD078]
 
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
Irving M., Zoete V., Bassani-Sternberg M., Coukos G., 2022/01/10. Cancer cell, 40 (1) pp. 20-22. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF0839215AF4]
 
Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma.
Mohsen M.O., Speiser D.E., Michaux J., Pak H., Stevenson B.J., Vogel M., Inchakalody V.P., de Brot S., Dermime S., Coukos G. et al., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e002927. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C41D094CADC7]
 
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E., Giordano Attianese GMP, Coukos G., Irving M., 2022. Frontiers in immunology, 13 p. 951143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BEC9380646B]
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O., Lalani A.K., Robert C., Sharma P., Peters S., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e003024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EB4E8449258]
Editorial: Immunopeptidomic Approaches for the Identification of Tumor (neo)Antigens.
Lill J.R., Bassani-Sternberg M., 2022. Frontiers in immunology, 13 p. 923776. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8DA1622055E1]
 
Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage
Cribioli E., Giordano Attianese GMP, Ginefra P., Signorino-Gelo A., Vuillefroy de Silly R., Vannini N., Hess C., Irving M., Coukos G., 2022. Frontiers in immunology, 13 p. 976628. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3101020C948F]
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V., Kurt M., Zhang L., Butler M.O., Michielin O., Amadi A., Hernlund E., Johnson H.M., Kotapati S., Moshyk A. et al., 2022. MDM policy & practice, 7 (1) p. 23814683221089659. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DDC4E311C75]
Impact of scanner variability on lymph node segmentation in computational pathology.
Khan A., Janowczyk A., Müller F., Blank A., Nguyen H.G., Abbet C., Studer L., Lugli A., Dawson H., Thiran J.P. et al., 2022. Journal of pathology informatics, 13 p. 100127. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5C4383C0E205]
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera F.G., Ronet C., Ochoa de Olza M., Barras D., Crespo I., Andreatta M., Corria-Osorio J., Spill A., Benedetti F., Genolet R. et al., 2022/01. Cancer discovery, 12 (1) pp. 108-133. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D82928F3BB2B]
 
Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.
Blanchard P., Lee AWM, Carmel A., Wai Tong N., Ma J., Chan ATC, Hong R.L., Chen M.Y., Chen L., Li W.F. et al., 2022/01. Clinical and translational radiation oncology, 32 pp. 59-68. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_22AE66170C77]
MMO-Net (Multi-Magnification Organ Network): A use case for Organ Identification using Multiple Magnifications in Preclinical Pathology Studies.
Gámez Serna C., Romero-Palomo F., Arcadu F., Funk J., Schumacher V., Janowczyk A., 2022. Journal of pathology informatics, 13 p. 100126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C481755AE74A]
Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.
Bajwa G., Arber C., 2022. Frontiers in immunology, 13 p. 830021. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0C6CE3A6605F]
Re-irradiation of recurrent vertebral metastasis after two previous spinal cord irradiation: A case report.
Bentahila R., Kinj R., Huck C., El Houat Y., Mampuya A., Tuleasca C., Ozsahin M., Bourhis J., Schiappacasse L., 2022. Frontiers in oncology, 12 p. 995376. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5064554EC04A]
 
Structural Prediction of Peptide–MHC Binding Modes
Perez Marta A. S., Cuendet Michel A., Röhrig Ute F., Michielin Olivier, Zoete Vincent, 2022. pp. 245-282 dans Computational Peptide Science, Springer US.
[DOI][Pmid][serval:BIB_5B61FB9FCC6D]
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
Matthaiou E.I., Guo Y., Barar J., Sandaltzopoulos R., Kandalaft L.E., Li C., Coukos G., Omidi Y., 2022. BioImpacts, 12 (1) pp. 65-86. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7205BBE80A2D]
2021
 
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
 
Synchrotron Microbeam Radiation Therapy for the Treatment of Lung Carcinoma: A Preclinical Study.
Trappetti V., Fernandez-Palomo C., Smyth L., Klein M., Haberthür D., Butler D., Barnes M., Shintani N., de Veer M., Laissue J.A. et al., 2021/12/01. International journal of radiation oncology, biology, physics, 111 (5) pp. 1276-1288. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5F5D0D4A4FC1]
 
Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard C.L., Delyon J., Wicky A., Homicsko K., Cuendet M.A., Michielin O., 2021/12. Cancer treatment reviews, 101 p. 102227. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AB33FCA1873]
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope.
Ebrahimi-Nik H., Moussa M., Englander R.P., Singhaviranon S., Michaux J., Pak H., Miyadera H., Corwin W.L., Keller GLJ, Hagymasi A.T. et al., 2021/11/05. Nature communications, 12 (1) p. 6423. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63F82E17F0C1]
 
Technical Note: Break-even dose level for hypofractionated treatment schedules.
Böhlen T.T., Germond J.F., Bourhis J., Vozenin M.C., Bailat C., Bochud F., Moeckli R., 2021/11. Medical physics, 48 (11) pp. 7534-7540. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A85E84A8CBCF]
 
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers M.L., Dimitriou F., Lau P., Bhave P., McArthur G.A., Zimmer L., Kudura K., Gérard C.L., Levesque M.P., Michielin O. et al., 2021/10. European journal of cancer, 156 pp. 149-163. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A82FBE1EAA00]
A promising platform for predicting toxicity.
Ochoa de Olza M., 2021/09/24. eLife, 10 pp. e73191. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3B55CEFF0A5A]
Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays.
Duchamp M., Arnaud M., Bobisse S., Coukos G., Harari A., Renaud P., 2021/09/06. Micromachines, 12 (9) p. 1076. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_550F1A17928D]
 
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
Lopes A.M.D.S., Colomer-Lahiguera S., Mederos-Alfonso N-N., Lopez V. Aedo, Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/09., ESMO Congress 2021 pp. S1180 dans Annals of Oncology.
[DOI][WoS][serval:BIB_8EB95DA9992D]
A new method to visualize and to spare the ureters during SBRT for oligo metastatic patients.
Muggeo-Bertin E., Moeckli R., Vallet V., Berthold D., Godin S., Bourhis J., Herrera F.G., 2021/09. Technical innovations & patient support in radiation oncology, 19 pp. 7-10. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_5205796889DB]
 
The role of fluorescent and hybrid tracers in radioguided surgery in urogenital malignancies.
DE Vries H.M., Schottelius M., Brouwer O.R., Buckle T., 2021/09. The quarterly journal of nuclear medicine and molecular imaging, 65 (3) pp. 261-270. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5F5C6091280A]
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle J.K., Brioschi M., de Tiani M., Wetterwald L., Atsaves V., Abram-Saliba J., Petrova T.V., Coukos G., Dunn S.M., 2021/08/17. Cell reports. Medicine, 2 (8) p. 100362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3930B2D62A38]
Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease.
Dietz M., Kamani C.H., Deshayes E., Dunet V., Mitsakis P., Coukos G., Nicod Lalonde M., Schaefer N., Prior J.O., 2021/08/14. EJNMMI research, 11 (1) p. 71. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BC418C20751B]
Sex-Specific Differences in Toxicity Following Systemic Paclitaxel Treatment and Localized Cardiac Radiotherapy.
Chmielewski-Stivers N., Petit B., Ollivier J., Monceau V., Tsoutsou P., Quintela Pousa A., Lin X., Limoli C., Vozenin M.C., 2021/08/06. Cancers, 13 (16) p. 3973. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC36C22A988A]
Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report.
Arangalage D., Pavon A.G., Özdemir B.C., Michielin O., Schwitter J., Monney P., 2021/08. European heart journal. Case reports, 5 (8) pp. ytab262. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2AAE474DB65]
 
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva I.P., Ahmed T., Reijers ILM, Warner A.B., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Zimmer L., Trojaniello C. et al., 2021/08. The Lancet. Oncology, 22 (8) pp. e343-e344. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D51407044D20]
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
Thouvenin L., Charrier M., Clement S., Christinat Y., Tille J.C., Frigeri M., Homicsko K., Michielin O., Bodmer A., Chappuis P.O. et al., 2021/08. Gynecologic oncology reports, 37 p. 100787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB2F51C1A9EA]
 
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Hepner A., Atkinson V.G., Larkin J., Burrell R.A., Carlino M.S., Johnson D.B., Zimmer L., Tsai K.K., Klein O., Lo S.N. et al., 2021/08. European journal of cancer, 153 pp. 213-222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1A7F34C37268]
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B098C62EF15]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University